Marketdash
Back to News

Agilent Gets Wall Street Upgrade Wave After Strong Quarter and Bullish Outlook

MarketDash Editorial Team
12 days ago
Agilent Technologies crushed fourth-quarter expectations and delivered guidance that blew past Wall Street forecasts, prompting at least six major analysts to raise their price targets on the life sciences company.

Agilent Technologies Inc. (A) just gave Wall Street analysts plenty of reasons to feel optimistic, and they're responding accordingly. The life sciences and diagnostics company reported fourth-quarter results on Monday that topped expectations, then followed up with forward guidance that suggests management sees much smoother sailing ahead than the Street had anticipated.

The numbers tell a pretty straightforward story. Agilent posted quarterly earnings of $1.59 per share, edging past the $1.58 consensus estimate. Revenue came in at $1.861 billion, comfortably above analyst projections of $1.832 billion. Not blowout beats, but solid execution.

What really caught attention, though, was the company's outlook for fiscal 2026. Agilent expects adjusted earnings per share between $5.86 and $6.00, a substantial jump from the market's $5.57 estimate. On the revenue side, the company is guiding to $7.3 billion to $7.4 billion versus Wall Street's more conservative $6.916 billion forecast. That's not a minor gap—it's the kind of guidance revision that makes analysts scramble to update their models.

"We enter FY26 with confidence and momentum. Agilent is uniquely positioned to lead in life-sciences and diagnostics for years to come," said Agilent President and CEO Padraig McDonnell. "Our progress this year reflects innovation built on a customer-focused approach that creates real value and extraordinary customer intimacy through a unified commercial organization that delivers a seamless end-to-end experience. Powered by our expanded Ignite Operating System, these strengths continue to unlock operating efficiencies, fuel innovation, enhance commercial execution, and create long-term value for customers and shareholders."

Investors liked what they heard. Agilent shares climbed 3.5% to $158.94 on Tuesday following the announcement.

The analyst community responded with a flurry of price target increases, even as most maintained their existing ratings on the stock. Here's the breakdown:

  • B of A Securities analyst Derik De Bruin kept a Neutral rating but raised his price target from $150 to $165.
  • Baird analyst Catherine Schulte maintained an Outperform rating and lifted her target from $142 to $165.
  • Barclays analyst Luke Sergott stuck with an Equal-Weight rating while bumping the target from $145 to $165.
  • JP Morgan analyst Casey Woodring maintained an Overweight rating and boosted the price target from $165 to $180.
  • Wells Fargo analyst Brandon Couillard kept an Overweight rating and raised his target from $150 to $175.
  • UBS analyst Dan Leonard maintained a Buy rating and increased the price target from $170 to $180.

The pattern here is telling—even analysts who remain cautious on the stock's rating couldn't ignore the improved financial trajectory. When guidance comes in that far ahead of expectations, price targets tend to follow upward, and that's exactly what happened across the board.

Back to News

Agilent Gets Wall Street Upgrade Wave After Strong Quarter and Bullish Outlook

MarketDash Editorial Team
12 days ago
Agilent Technologies crushed fourth-quarter expectations and delivered guidance that blew past Wall Street forecasts, prompting at least six major analysts to raise their price targets on the life sciences company.

Agilent Technologies Inc. (A) just gave Wall Street analysts plenty of reasons to feel optimistic, and they're responding accordingly. The life sciences and diagnostics company reported fourth-quarter results on Monday that topped expectations, then followed up with forward guidance that suggests management sees much smoother sailing ahead than the Street had anticipated.

The numbers tell a pretty straightforward story. Agilent posted quarterly earnings of $1.59 per share, edging past the $1.58 consensus estimate. Revenue came in at $1.861 billion, comfortably above analyst projections of $1.832 billion. Not blowout beats, but solid execution.

What really caught attention, though, was the company's outlook for fiscal 2026. Agilent expects adjusted earnings per share between $5.86 and $6.00, a substantial jump from the market's $5.57 estimate. On the revenue side, the company is guiding to $7.3 billion to $7.4 billion versus Wall Street's more conservative $6.916 billion forecast. That's not a minor gap—it's the kind of guidance revision that makes analysts scramble to update their models.

"We enter FY26 with confidence and momentum. Agilent is uniquely positioned to lead in life-sciences and diagnostics for years to come," said Agilent President and CEO Padraig McDonnell. "Our progress this year reflects innovation built on a customer-focused approach that creates real value and extraordinary customer intimacy through a unified commercial organization that delivers a seamless end-to-end experience. Powered by our expanded Ignite Operating System, these strengths continue to unlock operating efficiencies, fuel innovation, enhance commercial execution, and create long-term value for customers and shareholders."

Investors liked what they heard. Agilent shares climbed 3.5% to $158.94 on Tuesday following the announcement.

The analyst community responded with a flurry of price target increases, even as most maintained their existing ratings on the stock. Here's the breakdown:

  • B of A Securities analyst Derik De Bruin kept a Neutral rating but raised his price target from $150 to $165.
  • Baird analyst Catherine Schulte maintained an Outperform rating and lifted her target from $142 to $165.
  • Barclays analyst Luke Sergott stuck with an Equal-Weight rating while bumping the target from $145 to $165.
  • JP Morgan analyst Casey Woodring maintained an Overweight rating and boosted the price target from $165 to $180.
  • Wells Fargo analyst Brandon Couillard kept an Overweight rating and raised his target from $150 to $175.
  • UBS analyst Dan Leonard maintained a Buy rating and increased the price target from $170 to $180.

The pattern here is telling—even analysts who remain cautious on the stock's rating couldn't ignore the improved financial trajectory. When guidance comes in that far ahead of expectations, price targets tend to follow upward, and that's exactly what happened across the board.